{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:58:15Z","timestamp":1767873495269,"version":"3.49.0"},"reference-count":73,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. One-third of patients with DN develop primary glomerulonephritis, and membranous nephropathy (MN) is the most common concurrent glomerulonephritis. Nephrotic syndrome (NS) due to DN and MN is often refractory to immunosuppressants because increased levels of low-density lipoprotein (LDL) not only accelerates kidney injury but also reduce the bioavailability of cyclosporine, a first-line immunosuppressant for MN. Given the pathological role of LDL, especially oxidized LDL, reducing LDL cholesterol levels can help achieve remission of NS and halt the progression of kidney injury. Although some lipoproteins are not excreted by the kidneys, excessive LDL, including oxidized LDL, can be considered uremic toxic-like factors that contribute to the development of NS or DN. We encountered a 74-year-old patient with concomitant DN and MN who achieved complete remission following additional LDL apheresis (LDL-A) with immunosuppressant therapy. Here, we provide a narrative review summarizing the role of LDL, especially ox-LDL, in the progression of DN and glomerulonephritis, including MN, and discuss the therapeutic rationale for LDL-A. We also present a representative case of concomitant MN and DN refractory to conventional immunosuppression who achieved clinical improvement following LDL-A.<\/jats:p>","DOI":"10.3390\/toxins18010029","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:01:29Z","timestamp":1767862889000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Pathological Role of LDL in Membranous Nephropathy and Diabetic Nephropathy and the Protective Efficacy of LDL Apheresis: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"given":"Goh","family":"Kodama","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-1809","authenticated-orcid":false,"given":"Kensei","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"},{"name":"Research Institute of Medical Mass Spectrometry, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusei","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Shibata","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Fukami","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1497449","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment","volume":"2021","author":"Samsu","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.ki.5000289","article-title":"Renal pathology in idiopathic membranous nephropathy: A new perspective","volume":"69","author":"Troyanov","year":"2006","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10157-012-0593-7","article-title":"Membranous nephropathy in Japan: Analysis of the Japan Renal Biopsy Registry (J-RBR)","volume":"16","author":"Yokoyama","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Busuioc, R., \u0218tefan, G., Stancu, S., Zugravu, A., and Mircescu, G. (2023). Nephrotic Syndrome and Statin Therapy: An Outcome Analysis. Medicina, 59.","DOI":"10.3390\/medicina59030512"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12020-024-03948-4","article-title":"Remnant cholesterol and the risk of diabetic nephropathy progression to end-stage kidney disease in patients with type 2 diabetes mellitus: A longitudinal cohort study","volume":"86","author":"Zhao","year":"2024","journal-title":"Endocrine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/gfr454","article-title":"High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes","volume":"27","author":"Carter","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"F909","DOI":"10.1152\/ajprenal.00160.2003","article-title":"Angiotensin II mediates LDL-induced superoxide generation in mesangial cells","volume":"285","author":"Park","year":"2003","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1172\/JCI8574","article-title":"Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species","volume":"105","author":"Podrez","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cvr\/cvp036","article-title":"RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice","volume":"82","author":"Sun","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and Molecular Mechanisms of Metformin Action","volume":"42","author":"LaMoia","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s41100-025-00646-3","article-title":"Annual dialysis data report 2022, Japanese Society for Dialysis Therapy (JSDT) Renal Data Registry","volume":"11","author":"Hanafusa","year":"2025","journal-title":"Ren. Replace. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice","volume":"121","author":"Hartleben","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6580195","DOI":"10.1155\/2022\/6580195","article-title":"Emerging Protective Actions of PGC-1\u03b1 in Diabetic Nephropathy","volume":"2022","author":"She","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Taguchi, K., and Fukami, K. (2023). RAGE signaling regulates the progression of diabetic complications. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1128872"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cytogfr.2014.04.002","article-title":"CXCL16 in kidney and cardiovascular injury","volume":"25","author":"Izquierdo","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Koopman, J.J.E., van Essen, M.F., Rennke, H.G., de Vries, A.P.J., and van Kooten, C. (2020). Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.599974"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Trambas, I.A., Coughlan, M.T., and Tan, S.M. (2023). Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108758"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.2015.162","article-title":"Macrophage-derived tumor necrosis factor-\u03b1 mediates diabetic renal injury","volume":"88","author":"Awad","year":"2015","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Donate-Correa, J., Tagua, V.G., Ferri, C., Mart\u00edn-N\u00fa\u00f1ez, E., Hern\u00e1ndez-Carballo, C., Ure\u00f1a-Torres, P., Ruiz-Ortega, M., Ortiz, A., Mora-Fern\u00e1ndez, C., and Navarro-Gonz\u00e1lez, J.F. (2019). Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030287"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial","volume":"3","author":"Bekker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/0886022X.2019.1605294","article-title":"Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy","volume":"41","author":"Chen","year":"2019","journal-title":"Ren. Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.mayocp.2023.08.006","article-title":"Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification","volume":"98","author":"Sethi","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: From models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1111\/j.1582-4934.2009.00761.x","article-title":"CXCL16 and oxLDL are induced in the onset of diabetic nephropathy","volume":"13","author":"Gutwein","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s10157-015-1216-x","article-title":"Evidence-based clinical practice guidelines for nephrotic syndrome 2014","volume":"20","author":"Nishi","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10157-020-01932-6","article-title":"The revised version 2018 of the nationwide web-based registry system for kidney diseases in Japan: Japan Renal Biopsy Registry and Japan Kidney Disease Registry","volume":"24","author":"Ozeki","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00007691-199107000-00002","article-title":"Plasma distribution of cyclosporine within lipoproteins and \u201cin vitro\u201d transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins","volume":"13","author":"Hughes","year":"1991","journal-title":"Ther. Drug Monit."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s10157-013-0930-5","article-title":"Beneficial effect of LDL-apheresis in refractory nephrotic syndrome","volume":"18","author":"Muso","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000437338","article-title":"A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome","volume":"5","author":"Muso","year":"2015","journal-title":"Nephron Extra"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0012.2005.00397.x","article-title":"Recurrent nephrotic syndrome after living-related renal transplantation resistant to plasma exchange: Report of two cases","volume":"19","author":"Masutani","year":"2005","journal-title":"Clin. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1744-9987.2008.00596.x","article-title":"A case report of nephrotic syndrome due to collapsing focal segmental glomerulosclerosis treated with low-density lipoprotein apheresis","volume":"12","author":"Miyazono","year":"2008","journal-title":"Ther. Apher. Dial."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10157-008-0078-x","article-title":"Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis","volume":"13","author":"Miura","year":"2009","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2169\/internalmedicine.54.4631","article-title":"Focal Segmental Glomerular Sclerosis Ameliorated by Long-term Hemodialysis Therapy with Low-density Lipoprotein Apheresis","volume":"54","author":"Araki","year":"2015","journal-title":"Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2169\/internalmedicine.8258-21","article-title":"Successful Treatment of Nephrotic Syndrome Due to Collapsing Focal Segmental Glomerulosclerosis Accompanied by Acute Interstitial Nephritis","volume":"61","author":"Shima","year":"2022","journal-title":"Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2169\/internalmedicine.1922-23","article-title":"Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series","volume":"63","author":"Shima","year":"2024","journal-title":"Intern. Med."},{"key":"ref_43","first-page":"46","article-title":"Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment","volume":"38","author":"Okada","year":"1996","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1046\/j.1365-2362.2000.00716.x","article-title":"LDL-apheresis in patients with nephrotic syndrome: Effects on serum albumin and urinary albumin excretion","volume":"30","author":"Stenvinkel","year":"2000","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_45","first-page":"25","article-title":"Usefulness of LDL-apheresis for treatment of steroid-resistant nephrotic syndrome","volume":"45","author":"Yoshizawa","year":"2003","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10157-007-0003-8","article-title":"Applications of LDL-apheresis in nephrology","volume":"12","author":"Kobayashi","year":"2008","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1744-9987.2011.01045.x","article-title":"Low density lipoprotein apheresis ameliorates interferon-\u03b3 production in patients with nephrotic syndrome","volume":"16","author":"Miyata","year":"2012","journal-title":"Ther. Apher. Dial."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/nep.13120","article-title":"The Efficacy of Low-Density Lipoprotein Apheresis in a Patient with Drug-Resistant Minimal Change Nephrotic Syndrome: A Case Report and A Review of the Literature","volume":"23","author":"Nakatani","year":"2018","journal-title":"Nephrology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/IJNRD.S248610","article-title":"Low-Density Lipoprotein Apheresis in Patients with Acute Kidney Injury Due to Minimal Change Disease Requiring Acute Renal Replacement Therapy","volume":"13","author":"Terada","year":"2020","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s13730-025-01016-y","article-title":"Early low-density lipoprotein apheresis for steroid-resistant minimal change disease with acute kidney injury: A case report","volume":"14","author":"Hiramatsu","year":"2025","journal-title":"CEN Case Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0041-1345(99)00941-0","article-title":"Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: A case report","volume":"32","author":"Ideura","year":"2000","journal-title":"Transpl. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2169\/internalmedicine.51.7204","article-title":"Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy","volume":"51","author":"Sato","year":"2012","journal-title":"Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2169\/internalmedicine.56.8081","article-title":"Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis","volume":"56","author":"Yabuuchi","year":"2017","journal-title":"Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jca.21677","article-title":"Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis","volume":"34","author":"Szymanski","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13730-020-00494-6","article-title":"Low-density lipoprotein apheresis for PLA2R-related membranous glomerulonephritis accompanied by IgG4-related tubulointerstitial nephritis","volume":"9","author":"Nishizawa","year":"2020","journal-title":"CEN Case Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13730-021-00630-w","article-title":"Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: A case report and literature review","volume":"11","author":"Nishizawa","year":"2022","journal-title":"CEN Case Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-020-01959-9","article-title":"Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"Alquist","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cyto.2011.04.003","article-title":"Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL-apheresis","volume":"55","author":"Stefanutti","year":"2011","journal-title":"Cytokine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2006.09.026","article-title":"Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis","volume":"377","author":"Utsumi","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26807","DOI":"10.1074\/jbc.C400163200","article-title":"Chemokines generally exhibit scavenger receptor activity through their receptor-binding domain","volume":"279","author":"Shimaoka","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.ajkd.2004.09.013","article-title":"Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy","volume":"45","author":"Nakamura","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2169\/internalmedicine.5455-20","article-title":"Anemia in Diabetic Patients Reflects Severe Tubulointerstitial Injury and Aids in Clinically Predicting a Diagnosis of Diabetic Nephropathy","volume":"60","author":"Ito","year":"2021","journal-title":"Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1046\/j.1523-1755.1998.00059.x","article-title":"Identification of oxidized low density lipoprotein in human renal biopsies","volume":"54","author":"Lee","year":"1998","journal-title":"Kidney Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2353\/ajpath.2009.080960","article-title":"CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein","volume":"174","author":"Gutwein","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1681\/ASN.2004080629","article-title":"Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase\/AKT-signaling pathway","volume":"16","author":"Bussolati","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s10157-020-01864-1","article-title":"Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: The Japan Nephrotic Syndrome Cohort Study (JNSCS)","volume":"24","author":"Yamamoto","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: Systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/dc19-0653","article-title":"Trends in Rates of Infections Requiring Hospitalization Among Adults with Versus Without Diabetes in the U.S., 2000\u20132015","volume":"43","author":"Harding","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10157-012-0746-8","article-title":"Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010","volume":"17","author":"Sugiyama","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/nep.12739","article-title":"Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China","volume":"22","author":"Tang","year":"2017","journal-title":"Nephrology"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/1\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:14:25Z","timestamp":1767863665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/1\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["toxins18010029"],"URL":"https:\/\/doi.org\/10.3390\/toxins18010029","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}